Oragenics Doses First Patient in Phase IIa Trial for Concussion Treatment ONP-002

Oragenics Inc. (NYSE American: OGEN), a clinical-stage biotechnology company focused on brain-targeted therapeutics, has dosed the first patient in its Phase IIa clinical trial evaluating ONP-002 for concussion and mild traumatic brain injury at Mackay Hospital in Australia. This milestone follows regulatory approval and site activation on March 31, 2026, marking significant progress in advancing a first-in-class intranasal neurosteroid designed to address underlying brain injury mechanisms. The company is expanding trial sites to target a large unmet medical need in a condition that currently lacks FDA-approved pharmacological treatments.

The development of ONP-002 represents a potentially transformative approach to concussion treatment, as current management primarily focuses on symptom relief and rest rather than addressing the underlying neurological damage. Concussion and mild traumatic brain injury affect millions of people annually worldwide, with athletes, military personnel, and accident victims being particularly vulnerable populations. The absence of approved pharmacological treatments has created a substantial market opportunity and critical medical need that Oragenics aims to address through its proprietary intranasal delivery technology.

Oragenics' intranasal delivery platform enables direct administration of therapeutics to the brain, potentially improving efficacy and reducing systemic side effects compared to traditional oral or intravenous routes. This technology has broader applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders, as noted in company materials available at https://oragenics.com. The Phase IIa trial in Australia represents an important step in the clinical development pathway, with U.S. Phase 2b trials planned to follow successful completion of the current study.

The company's progress comes at a time when awareness of concussion-related long-term consequences, including chronic traumatic encephalopathy (CTE) and post-concussion syndrome, has increased significantly across medical communities and the general public. Successful development of ONP-002 could establish a new standard of care for concussion management and potentially reduce long-term neurological complications. For investors and stakeholders following the company's developments, additional information is available through the company's newsroom at https://ibn.fm/OGEN, which provides updates on Oragenics' progress in neurological therapeutics development.

The clinical trial advancement also highlights the growing importance of specialized research in traumatic brain injury, a field that has historically received less attention and funding than other neurological disorders despite its significant public health impact. Oragenics' approach of targeting specific neurobiological mechanisms represents a shift toward more targeted therapeutic interventions in brain injury. As the trial progresses, results will be closely monitored by both the medical community and investors interested in the potential of brain-targeted therapeutics to address conditions with limited treatment options.